Posters

Clinical outcomes after implantation of a posterior chamber collagen copolymer phakic intraocular lens with a central hole for myopic correction

Poster Details

First Author: D.Mathur INDIA

Co Author(s):    N. Shroff   R. Dutta                 

Abstract Details

Purpose:

To evaluate the efficacy, predictability, safety and stability of a posterior chamber Implantable Collamer Phakic Intraocular Lens (pIOL) (V4C Visian ICL with Centraflow, STAAR Surgicals) to correct myopia and astigmatism.

Setting:

Cornea & Refractive Service, Shroff Eye Centre, Kailash Colony, New Delhi, India.

Methods:

186 eyes of 95 patients underwent implantation of a new pIOL design with a central hole for more natural aqueous follow, eliminating the need for neodymium: YAG iridotomy or peripheral iridectomy. The uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refractive error, intraocular pressure (IOP), endothelial cell count, central vault, and adverse events were evaluated 12 months postoperatively.

Results:

The mean spherical equivalent decreased from –10.21±3.24 D preoperatively to –0.04±0.21 D 12 months postoperatively; 92.5% of eyes were with ±0.50 D and 97.8% of eyes were within ±1.00 D. The mean UDVA and CDVA were 20/20 or better in 90.9% and 97.8% of eyes, respectively, at 12 months. The safety and efficacy indices were 1.02 and 0.98 respectively. Postoperatively, the IOP remained stable over time. No secondary cataract, significant rise in IOP or pupillary block was detected. After 12 months, the mean vault was 532.9±171.3 microns (range 141 to 1021) and the mean endothelial cell loss was 6.52%.

Conclusions:

Implantation of the pIOL was effective, predictable, safe, and stable for correction of moderate to high myopic errors. The Centraflow design, which avoids iridotomy or iridectomy, provides good IOP outcomes with high patient satisfaction.

Financial Disclosure:

NONE